Table 1 The response to treatment in... | American Society of Hematology

Table 1

The response to treatment in different APL models

	PML-RARα					PLZF-RARα
	RA_low	RA_medium	RA_high	As₂O₃	RA_medium/As₂O₃	RA_low	RA_high
Ex vivo
Differentiation	+	++	+++	−	+	+	+++
Degradation	−	+++	+++	+++	+++	−	+++
LIC loss	−	+++	+++	+++	+++	−	+++
In vivo
Differentiation	++	+++	+++	+	++	++	+++
Degradation	−	++	+++	++	+++	−	++
LIC loss	−	++	+++	+*	+++	−	+
In patients
Differentiation	+++	+++	+++	++	+++	++	++
Cure	−	+	+++	+++	+++	−	−/+†

	PML-RARα					PLZF-RARα
	RA_low	RA_medium	RA_high	As₂O₃	RA_medium/As₂O₃	RA_low	RA_high
Ex vivo
Differentiation	+	++	+++	−	+	+	+++
Degradation	−	+++	+++	+++	+++	−	+++
LIC loss	−	+++	+++	+++	+++	−	+++
In vivo
Differentiation	++	+++	+++	+	++	++	+++
Degradation	−	++	+++	++	+++	−	++
LIC loss	−	++	+++	+*	+++	−	+
In patients
Differentiation	+++	+++	+++	++	+++	++	++
Cure	−	+	+++	+++	+++	−	−/+†

The loss of LICs is assessed by serial replating ex vivo or transplantation in vivo.

Ex vivo indicates PML-RARA-transformed murine hematopoietic progenitor cells in methylcellulose cultures; in vivo, APL transgenic murine models.

As₂O₃ displays attenuated effects in mice due to dosage or pharmacokinetics issues.

Rare patients have been reported to respond to RA treatment by itself.